Artificial Intelligence (AI) is revolutionizing the biopharmaceutical (biopharma) industry, particularly in research and development (R&D). From accelerating drug discovery to predicting clinical trial outcomes, AI is enabling unprecedented scientific breakthroughs. However, as the industry integrates AI deeper into R&D workflows, it must confront a parallel

The biopharmaceutical industry, while central to global health, is increasingly under scrutiny for its environmental footprint. From energy-intensive manufacturing processes to waste generation and water use, biopharma’s ecological impact is significant. Yet, the industry is undergoing a green transformation, driven by regulatory pressure, investor expectations,

In an industry long driven by innovation, compliance, and scientific breakthroughs, environmental, social, and governance (ESG) performance is becoming a new benchmark of excellence in biopharma. The shift is clear: investors are not only looking at drug pipelines and quarterly revenues—they're also scrutinizing carbon footprints,

In recent years, artificial intelligence (AI) has emerged as a powerful tool in drug discovery, with promises of dramatically reducing the time, cost, and complexity of bringing new drugs to market. Headlines often tout AI as a game-changer capable of revolutionizing the pharmaceutical industry. However,

As the biopharmaceutical industry evolves to meet increasing global demand for biologics, vaccines, and cell and gene therapies, it faces a dual imperative: scalability and sustainability. Single-use technologies (SUTs)—disposable bioprocessing components made primarily from polymers—have rapidly gained traction as a solution that meets both needs.